Immediately: Billing team must log into the InTouch for Providers portal and verify current authorization dates for all extended medications and medical benefit drugs listed in this policy. Update internal authorization tracking systems to reflect new expiration dates. For commercial members, note 5-year extensions from authorization start dates; for Medicaid members, note 1-year extensions. Affected drugs include: Cosentyx, Cimzia, Enbrel, Orencia, Otezla, Rinvoq, Skyrizi, Dupixent, Fasenra, Nucala, Tezspire, Xolair, Adalimumab biosimilars (Adalimumab-ADAZ, Adalimumab-FKJP, Hadlima, Hyrimoz), Ustekinumab biosimilars (Selarsdi, Yesintek), Briviact, Epidiolex, Pulmozyme, Trikafta, Winrevair, Sildenafil 20mg (PAH), Tadalafil 20mg (PAH), Botox, Dysport, Xeomin, Eylea, Eylea HD, Vabysmo, Vyepti, Infliximab biosimilars (Avsola, Inflectra, Renflexi), Tocilizumab biosimilars (Tofidence, Tyenne), Benlysta, Saphnelo, and Rituximab biosimilars (Riabni, Ruxience, Truxima). Front desk and claims processing staff must reference updated authorization dates when verifying eligibility. Failure to update records may result in claim denials for expired authorizations.